Journal
AIMS PUBLIC HEALTH
Volume 8, Issue 4, Pages 720-742Publisher
AMER INST MATHEMATICAL SCIENCES-AIMS
DOI: 10.3934/publichealth.2021057
Keywords
COVID-19; diabetes mellitus; chronic inflammation; impaired immune system; SARS-CoV-2 receptor; ACE2 polymorphisms; diabetogenic effect
Categories
Funding
- program 2do ano de continuidad de estancias posdoctorales vinculadas al fortalecimiento de la calidad del posgrado nacional - Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico [I1200/94/2020]
- CONACyT
Ask authors/readers for more resources
Patients with diabetes mellitus have a higher risk of developing severe complications in COVID-19 due to factors such as hyperglycemia, weakened immunity, chronic inflammation, and other comorbidities commonly seen in diabetes. The role of SARS-CoV-2 receptor and its variations in individuals with diabetes may contribute to the higher susceptibility to severe outcomes in COVID-19.
Diabetes mellitus (DM) has a high incidence of comorbidities among patients with severe coronavirus disease 2019 (COVID-19). The elevated prevalence of DM in the world population makes it a significant risk factor because diabetic individuals appear to be prone to clinical complications and have increased mortality rates. Here, we review the possible underlying mechanisms involved in DM that led to worse outcomes in COVID-19. The impacts of hyperglycemia side effects, secondary comorbidities, weakened innate and adaptive immunity, chronic inflammation, and poor nutritional status, commonly present in DM, are discussed. The role of the SARS-CoV-2 receptor and its polymorphic variations on higher binding affinity to facilitate viral uptake in people with DM were also considered. Clinical differences between individuals with type 1 DM and type 2 DM affected by COVID-19 and the potential diabetogenic effect of SARS-CoV-2 infection were addressed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available